Q32 Bio Inc. — Form 8-K Summary
Filing date: September 30, 2026. The 8-K reports clinical-trial results and development plans; it does not provide a financial-statement update. The disclosed results concern Part B of the Phase 2a SIGNAL-AA trial of bempikibart in severe or very severe alopecia areata.
Business context and results
- Part B was an open-label trial of 33 patients with baseline SALT scores of 50–100. Patients received subcutaneous bempikibart for 36 weeks, followed by a 16-week off-drug follow-up; 36.4% had prior oral JAK inhibitor exposure.
- At Week 36, mean SALT score declined 35.3% in the modified intent-to-treat (mITT) analysis. SALT-20 responses were 40.0% (10/25) in mITT and 30.3% (10/33) in intent-to-treat (ITT); SALT 30 and SALT 50 responses were each 44.0% (11/25) in mITT and 33.3% (11/33) in ITT.
- Among 18 patients entering off-drug follow-up, 44% achieved SALT-20, 61% SALT 30, and 50% SALT 50 at Week 52. Of 12 patients with hair growth by Week 36, all maintained response under the company’s definition; 42% deepened their response.
- In the mITT subgroup previously treated with oral JAK inhibitors, mean SALT reduction was 48.3% among prior JAK responders and 4.8% among prior non-responders; JAK-naïve patients had a 44.1% reduction. These are small subgroups.
Safety and other findings
- The company described safety as generally well tolerated, with no new safety signals and no treatment-related serious or Grade 3 or higher adverse events reported.
- Injection-site reactions occurred in 36.3% of patients; the company said they were mild and resolved without intervention. It also reported negligible anti-drug antibodies and pharmacodynamic and biopsy findings consistent with target engagement and hair growth.
Outlook, risks, and financial information
- Q32 plans, subject to regulatory discussions anticipated in the second half of 2026, to advance bempikibart into a registration-directed program for severe or very severe alopecia areata in the first half of 2027. Part B open-label extension data are anticipated in the second half of 2027.
- The company says ongoing off-drug and extension analyses will inform possible long-term maintenance dosing. It is also evaluating other alopecia areata populations and additional autoimmune or inflammatory indications.
- These plans and clinical interpretations are forward-looking and uncertain. The filing cites risks including whether further analyses will support the observed efficacy and durability, clinical-study costs and outcomes, cash runway, and the possibility that additional financing may be needed.
- Revenue, profit or loss, cash flow, margins, debt, liquidity, and other financial metrics are not stated in this filing; no clear values are provided for comparison with a prior period.
Important facts for investors to verify
- Review the full trial presentation and later analyses, including patient disposition, missing data, and the different mITT, ITT, and off-drug denominators.
- Track regulatory discussions, the timing and design of the planned registration-directed program, and whether the 2027 milestones are achieved.
- Assess durability and safety in larger, controlled studies; Part B was a small, open-label trial.
- Consult the company’s latest periodic filings for current cash, cash runway, financing needs, and other financial information.